可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Agabiti-Rosei E,Muiesan ML.Left ventricular hypertrophy and heart failure in women [J].J Hypertens,2002,20(suppl2):S34-S38.
[2] 惠波,郝玉明,刘凡,等.卡维地洛的分子血管保护作用[J].中国新药杂志,2000,9(4):229-231.
[3] Eichstaedt H, Schroedder RJ, Auffermann W, etal. Regression of left ventricular hypertrophy [J] . J Cardiovasc Pharmacol,1992,19(Suppl1):S55-S61
[4] Weber KT, Brilla CG.Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin- aldosterone system [J] .Circulation, 1991,83(6):1849-1865.
[5] Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors [J]. Cardiovasc Res,1993,27(3):341-348.
[6] Krzesinski JM, Rorive G,Van Gauwenberge H.Hypertension and ventricular hypertrophy [J]. Acta Cardiologica,1996,51(2):143-154.
[7]杨学东,赵连友,李雪,等.精氨酸加压素诱导大鼠心脏成纤维细胞胶原合成的作用[J].心脏杂志,2000,12(3):169-171.
[8]刘海林,杨少平,陆汉明,等.维拉帕米、硝苯地平对人成纤维细胞增殖、胶原和透明质酸合成的抑制作用[J].中国药理学通报,1996,12(5):456-458.
[9]Kurz T,Richardt D,Gorge B,et al.Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart[J].J Cardiovasc Pharmacol, 2000, 36 (1):96-100.